Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10735 | STAG2 | 052095_1628-all-cells | Human | Prostate | BPH | 1.22e-08 | 4.04e-01 | 0.1032 |
10735 | STAG2 | 052097_1595-all-cells | Human | Prostate | BPH | 1.60e-09 | 3.71e-01 | 0.0972 |
10735 | STAG2 | 052099_1652-all-cells | Human | Prostate | BPH | 2.35e-15 | 4.49e-01 | 0.1038 |
10735 | STAG2 | Dong_P1 | Human | Prostate | Tumor | 2.40e-21 | 7.37e-02 | 0.035 |
10735 | STAG2 | Dong_P3 | Human | Prostate | Tumor | 9.37e-14 | 4.95e-02 | 0.0278 |
10735 | STAG2 | Dong_P4 | Human | Prostate | Tumor | 4.81e-04 | -3.35e-03 | 0.0292 |
10735 | STAG2 | Dong_P5 | Human | Prostate | Tumor | 2.15e-30 | -1.32e-02 | 0.053 |
10735 | STAG2 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 3.08e-04 | 6.69e-01 | 0.1557 |
10735 | STAG2 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.73e-12 | 7.06e-01 | 0.1633 |
10735 | STAG2 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.03e-16 | 6.98e-01 | 0.1608 |
10735 | STAG2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 9.48e-11 | 6.79e-01 | 0.1604 |
10735 | STAG2 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.92e-05 | 5.45e-01 | 0.1621 |
10735 | STAG2 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 1.02e-04 | 6.15e-01 | 0.1619 |
10735 | STAG2 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.64e-02 | 6.27e-01 | 0.159 |
10735 | STAG2 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 5.28e-13 | 6.86e-01 | 0.1602 |
10735 | STAG2 | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 9.75e-05 | 6.47e-01 | 0.1537 |
10735 | STAG2 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 4.86e-06 | 6.74e-01 | 0.1608 |
10735 | STAG2 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 2.53e-05 | 7.57e-01 | 0.1622 |
10735 | STAG2 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.07e-03 | 2.71e-01 | 0.1575 |
10735 | STAG2 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.08e-04 | 1.82e-01 | 0.1545 |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAG2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAG2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAG2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STAG2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAG2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAG2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAG2 | SNV | Missense_Mutation | novel | c.1222N>A | p.Glu408Lys | p.E408K | Q8N3U4 | protein_coding | tolerated(0.39) | possibly_damaging(0.498) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
STAG2 | SNV | Missense_Mutation | | c.2093A>G | p.His698Arg | p.H698R | Q8N3U4 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
STAG2 | SNV | Missense_Mutation | novel | c.1416G>T | p.Glu472Asp | p.E472D | Q8N3U4 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
STAG2 | SNV | Missense_Mutation | | c.1234N>T | p.Asn412Tyr | p.N412Y | Q8N3U4 | protein_coding | tolerated(0.1) | possibly_damaging(0.568) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAG2 | SNV | Missense_Mutation | novel | c.206G>A | p.Arg69Gln | p.R69Q | Q8N3U4 | protein_coding | tolerated(0.24) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAG2 | SNV | Missense_Mutation | | c.1456G>A | p.Asp486Asn | p.D486N | Q8N3U4 | protein_coding | deleterious(0) | possibly_damaging(0.777) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
STAG2 | SNV | Missense_Mutation | | c.3385C>T | p.Pro1129Ser | p.P1129S | Q8N3U4 | protein_coding | tolerated(0.37) | benign(0.013) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
STAG2 | SNV | Missense_Mutation | | c.1678A>T | p.Arg560Trp | p.R560W | Q8N3U4 | protein_coding | deleterious(0.01) | possibly_damaging(0.908) | TCGA-D8-A1X5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
STAG2 | SNV | Missense_Mutation | | c.1712T>C | p.Leu571Pro | p.L571P | Q8N3U4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAG2 | SNV | Missense_Mutation | | c.832C>G | p.Gln278Glu | p.Q278E | Q8N3U4 | protein_coding | tolerated(0.06) | benign(0.415) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Trametinib | TRAMETINIB | 27500726 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Camptothecin | CAMPTOTHECIN | 21852505,24356817 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Dabrafenib | DABRAFENIB | 27500726 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Temozolomide | TEMOZOLOMIDE | 21852505,24356817 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Olaparib | OLAPARIB | 21852505,24356817 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | VEMURAFENIB | VEMURAFENIB | 27500726 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Vemurafenib | VEMURAFENIB | 27500726 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Rucaparib | RUCAPARIB | 21852505,24356817 |
10735 | STAG2 | CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Veliparib | VELIPARIB | 21852505,24356817 |